In this study, we developed and characterized a novel bispecific T-cell engager (BiTE) targeting tissue factor (TF) and CD3 and demonstrated its potent cytotoxic activity against cervical cancer cell lines. This evidence concerns the gene F3 and cervical carcinoma.